Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Addiction
Daniel PolskyGeorge E Woody

Abstract

The objective is to estimate cost, net social cost and cost-effectiveness in a clinical trial of extended buprenorphine-naloxone (BUP) treatment versus brief detoxification treatment in opioid-dependent youth. Economic evaluation of a clinical trial conducted at six community out-patient treatment programs from July 2003 to December 2006, who were randomized to 12 weeks of BUP or a 14-day taper (DETOX). BUP patients were prescribed up to 24 mg per day for 9 weeks and then tapered to zero at the end of week 12. DETOX patients were prescribed up to 14 mg per day and then tapered to zero on day 14. All were offered twice-weekly drug counseling. 152 patients aged 15-21 years. Data were collected prospectively during the 12-week treatment and at follow-up interviews at months 6, 9 and 12. The 12-week out-patient study treatment cost was $1514 (P < 0.001) higher for BUP relative to DETOX. One-year total direct medical cost was only $83 higher for BUP (P = 0.97). The cost-effectiveness ratio of BUP relative to DETOX was $1376 in terms of 1-year direct medical cost per quality-adjusted life year (QALY) and $25,049 in terms of out-patient treatment program cost per QALY. The acceptability curve suggests that the cost-effectiveness ratio...Continue Reading

References

Jan 13, 1996·Lancet·R P Mattick, W Hall
Jan 15, 1996·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·J P Santell
Nov 21, 1997·Medical Care·P Dolan
Aug 10, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·R A HirthW G Weissert
Mar 26, 2003·Statistics in Medicine·D Y Lin
Aug 23, 2003·Biostatistics·D Y Lin
Sep 6, 2003·Drug and Alcohol Dependence·Christopher M DoranJames Bell
Sep 1, 2005·Addiction·Ellen Meara, Richard G Frank
Oct 6, 2005·Archives of General Psychiatry·Lisa A MarschJohn Brooklyn
Sep 6, 2007·Pediatric Neurosurgery·Jill C Glick, Kelley Staley
Jan 4, 2008·The Journal of Behavioral Health Services & Research·Kathryn E McCollisterColleen A Halliday-Boykins
Sep 27, 2008·Drug and Alcohol Dependence·Geetha A SubramaniamKen Kolodner
Nov 6, 2008·JAMA : the Journal of the American Medical Association·George E WoodyPaul Fudala
Jan 15, 2010·Drug and Alcohol Dependence·Kathryn E McCollisterHai Fang

❮ Previous
Next ❯

Citations

Jan 5, 2012·Journal of General Internal Medicine·Bruce R SchackmanDavid A Fiellin
Dec 18, 2013·Journal of Substance Abuse Treatment·Joseph TkaczCharles Ruetsch
Feb 2, 2011·Pediatric Clinics of North America·Gabriel Kaplan, Iliyan Ivanov
May 24, 2016·Journal of Substance Abuse Treatment·Sharon ReifMaureen T Stewart
Apr 11, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Giovanni C SantoroStephen L Dewey
Jun 3, 2015·The Cochrane Database of Systematic Reviews·Amanda E PerryCatherine Hewitt
Jun 3, 2015·The Cochrane Database of Systematic Reviews·Amanda E PerryCatherine Hewitt
Jun 3, 2015·The Cochrane Database of Systematic Reviews·Amanda E PerryCatherine Hewitt
Aug 16, 2014·Addiction Science & Clinical Practice·Frances L LynchDavid Pating
Apr 30, 2014·The Cochrane Database of Systematic Reviews·Silvia MinozziMarina Davoli
Jun 25, 2014·The Cochrane Database of Systematic Reviews·Silvia MinozziMarina Davoli
Feb 14, 2018·Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention·Caleb J Banta-GreenDennis M Donovan
Feb 22, 2017·The Cochrane Database of Systematic Reviews·Linda GowingDalitso Mbewe
May 11, 2017·The Journal of Behavioral Health Services & Research·Traci R RieckmannAmanda J Abraham
Nov 14, 2017·The Medical Journal of Australia·Matthew P HamiltonPatrick D McGorry
Mar 24, 2016·PharmacoEconomics·Sean M Murphy, Daniel Polsky
Feb 13, 2021·Journal of Health Economics·Sarah Hamersma, Johanna Catherine Maclean
Mar 30, 2020·Journal of Substance Abuse Treatment·Ali JalaliSean M Murphy
Mar 2, 2021·Journal of Addictions Nursing·Yu-Ping Chang, Traci Raynor
Apr 30, 2021·Early Intervention in Psychiatry·Jean Nicolas WestenbergReinhard M Krausz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.